DPOAE changes in young children with confirmed hearing loss due to ototoxicity

Australian and New Zealand Journal of Audiology

Volumn 28, Issue 2, 2006, Pages 90-105

  Beahan, Nuala ^a,b,e   Reichman, Emma ^a   Kei, Joseph ^a   Driscoll, Carlie ^a   Young, June ^b   Suppiah, Ram ^c   Grohn, Mary Lou ^b   Sockalingam, Ravi ^d   Charles, Bruce ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Mater Health Services   (Australia)

^c MATER CHILDREN S HOSPITAL   (Australia)

^d DALHOUSIE UNIVERSITY   (Canada)

^e MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548822138     PISSN: 01571532     EISSN: None     Source Type: Journal    
DOI: 10.1375/audi.28.2.90     Document Type: Article

References (56)

1. American Speech-Language-Hearing Association. (1988). Tutorial: Tympanometry. Journal of Speech and Hearing Disorders, 53, 354-377.
2. American Speech-Language-Hearing Association. (1994). Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA, 36(Suppl.), 11-19.
3. Arslan, E., Orzan, E., & Santarelli, R. (1999). Global problem of drug-induced hearing loss. Annals of the New York Academy of Sciences, 884, 1-14.
4. Astbury, P.J., & Read, N.G. (1982). Kanamycin induced ototoxicity in the laboratory rat. Archives of Toxicology, 50, 267-278.
5. Beahan, N., Kei, J., O'Rourke, C., Sockalingham, R., Smyth, V., Young, J., et al. (2001). Feasibility of establishing an early indicator for ototoxicity in children using otoacoustic emissions. Asia Pacific Journal of Speech, Language, and Hearing, 6, 117-127.
6. Bernig, T., Weigel, S., Mukodzi, S., & Reddemann, H. (2000). Antibiotic sequential therapy for febrile neutropenia in pediatric patients with malignancy. Pediatric Hematology and Oncology, 17, 1, 93-98.
7. Bergeron, C., Dubourg, I., Chastagner, P., Mechinaud, F., Plouvier, E., Desfachelles, A., et al. (2005). Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectahle neuroblastoma: results of the SFOP NBL90 study. Pediatric Blood and Cancer, 45, 32-36.
8. Brown, A., McDowell, B., & Forge, A. (1989). Acoustic distortion products can be used to monitor the effects of chronic gentamicin treatment. Hearing Research, 42, 143-156.
9. Brummet, R., & Morrison, R. (1990). The incidence of aminoglycoside antibiotic induced hearing loss. Archives of Otolaryngology, Head and Neck Surgery, 116, 406-410.
10. Campbell, K., & Durrant, J. (1993). Audiologic monitoring for ototoxicity. Otolaryngologic Clinics of North America, 26, 903-914.
11. Dorn, P., Piskorski, P., Gorga, M., Neely, S., & Keefe, D. (1999). Predicting audiometric status from distortion product ototacoustic emissions using multivariate analyses. Ear and Hearing, 20, 149-163.
12. Dreschler, W., van der Hulst, R., Tange, R., & Urbanus, N. (1985). The role of high-frequency audiometry in early detection of ototoxicity. Audiology, 24, 387-395.
13. Freilich, R., Kraus, D., Budnick, A., Bayer, L., & Finlay, J. (1996). Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Medical and Pediatric Oncology, 26, 95-100.
14. Gorga, M.P., Neely, S.T., Bergman, B., Beauchaine, K.L., Kaminski, J.R., Peters, J., et al. (1993). A comparison of transient-evoked and distortion product otoacoustic emissions in normal-hearing and hearing-impaired subjects. Journal of the Acoustical Society of America, 93, 2639-2648.
15. Hale, G., Marina, N., Jones-Wallace, D., Greenwald, C., Jenkins, J., Rao, B., et al. (1999). Late effects of treatment for germ cell tumors during childhood and adolescence. Journal of Pediatric Hematology/ Oncology, 21, 115-122.
16. Hall, J. (2000). Handbook of otoacoustic emissions. San Diego CA: Singular/Thompson Learning.
17. Hansen, S. (1992). Late-effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin. Danish Medical Bulletin, 3, 391-399.
18. Harris, F., Lonsbury-Martin, B., Stagner, B., Coats, A., & Martin, G. (1989). Acoustic distortion products in humans: Systematic changes in amplitudes as a function of f2/f1 ratio. Journal of the Acoustical Society of America, 85, 220-229.
19. Harris, F., & Probst, R. (1997). Otoacoustic emissions and audiometric outcomes. In M.S. Robinette & T.J. Glattke (Eds.), Otoacoustic emissions: Clinical applications (pp 151-180). New York: Thieme.
20. Hotz, M.A., Harris, F.P., & Probst, R. (1994). Otoacoustic emissions: An approach for monitoring aminoglycoside-induces ototoxicity. Laryngoscope, 104, 1130-1134.
21. Huizing, E.H., & deGroot, J.C.M.J. (1987). Human cochlea pathology in aminoglycoside ototoxicity - A review. Acta Oto-laryngologica, 436, 117-125.
22. Hunter-Duvar, I.M., & Mount, R.J. (1978). The organ of corti following ototoxic antibiotic treatment. Scanning Electron Microscopy, 2, 423-430.
23. Jerger, J. (1970). Clinical experience with impedance audiometry. Archives of Otolaryngology Head and Neck Surgery, 92, 311-324.
24. Kakigi, A., Hirakawa, H., Harel, N., Mount, R.J., & Harrison, R.V. (1998). Basal cochlear lesions result in increased amplitude of otoacoustic emissions. Audiology and Neuro-otology, 3, 361-372.
25. Katbamna, B., Homnick, D., & Marks, J.H. (1999). Effects of chronic tobramycin treatment on distor-tion product otoacoustic emissions. Ear and Hearing, 20, 393-402.
26. Kemp, D.T. (1997). Otoacoustic emissions in perspective. In M.S. Robinette & T.J. Glattke (Eds.), Otoacoustic emissions: Clinical applications (pp. 1-21). New York: Thieme.
27. Kennedy, I., Fitzharris, B., Colls, B., & Atkinson, C. (1990). Carboplatin is ototoxic. Cancer, Chemotherapy and Pharmacology, 26, 232-234.
28. Kon, K., Inagaki, M., & Kaga, M. (2000). Developmental changes of distortion product and transient evoked otoacoustic emissions in different age groups. Brain Development, 22, 41-46.
29. Lee, J., & Kim, J. (1999). The maximum permissible ambient noise and frequency-specific averaging time on the measurement of distortion product otoacoustic emissions. Audiology, 38, 19-23.
30. Littman, T.A., Magruder, A., & Strother, D.R. (1998). Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: Pediatric case study. Journal of the American Academy of Audiohgy, 9, 257-262.
31. Lonsbury-Martin, B.L., Martin, G.K., Probst, R., & Coats, A.C. (1987). Acoustic distortion products in rabbit ear canal. I. Basic features and physiological vulnerability. Hearing Research, 28, 173-189.
32. Lonsbury-Martin, B.L., Martin, G.K., McCoy, M.J., & Whitehead, M.L. (1995). New approaches to the evaluation of the auditory system and a current analysis of otoacoustic emissions. Otolaryngology Head and Neck Surgery, 112, 50-63.
33. Marco-Algarra, J., Basterra, J., & Marco, J. (1985). Cis-diaminedichloro platinum ototoxicity. Acta Otolaryngologica, 99, 343-347.
34. Mills, C.D., Loos, B.M., & Henley, C.M. (1999). Increased susceptibility of male rats to kanamycin-induced cochleotoxicity. Hearing Research, 128, 75-79.
35. Mulheran, M., & Degg, C. (1997). Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. British Journal of Audiology, 31, 5-9.
36. Musiek, F., & Baran, J. (1997). Distortion product otoacoustic emissions: Hit and false-positive rates in normal-hearing and hearing-impaired subjects. American Journal of Otology, 18, 454-61.
37. Nakai, Y., Konishi, K., Chang, K., Ohashi, K., Morisaki, N., Minowa, Y., & Morimoto, A. (1982). Ototoxicity of the anticancer drug cisplatin. Acta Otolaryngologica, 93, 227-232.
38. Nicholas, S., Kei, J., Woodyatt, G., & McPherson, B. 1999. Otoacoustic emission findings in Rett Syndrome. Journal of the American Academy of Audiology, 10, 436-444.
39. Parsons, S., Neault, M., Lehmann, L., Brennan, L., Eickhoff, C., Kretschmar, C., et al. (1998). Severe ototoxicity following carboplatin- containing conditioning regimen for autologous marrow transplantation. Bone marrow transplant, 22, 669-674.
40. Pasic, T., & Dobie, R. (1991). Cis-platinum ototoxicity in children. Laryngoscope, 101, 985-991.
41. Peters, U., Preisler-Adams, S., Lavers-Kaminsky, C., Jurgens, H., & Lamprecht-Dinnesen, A. (2003). Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Research, 23, 1249-1256.
42. Ress, B., Sridhar, K., Balkany, T., Waxman, G., Stagner, B., & Lonsbury-Martin, B. (1999). Effects of cis-platin chemotherapy on otoacoustic emissions: The development of an objective screening protocol. Otolaryngology Head and Neck Surgery, 121, 693-701.
43. Schweitzer, V.O. (1993). Ototoxicity of chemotherapeutic agents. Otolaryngologic Clinics of North America, 26, 759-789.
44. Seligmann, H., Podoshin, L., Ben-David, J., Fradis, M., & Goldsher, M. (1996). Drug-induced tinnitus and other hearing disorders. Drug Safety, 14, 198-212.
45. Shi, Y., & Martin, W.H. (1997). ABR and DPOAE detection of cochlear damage by gentamicin. Journal of Basic Clinical Physiology and Pharmacology, 8, 141-155.
46. Stern, J., & Bunin, N. (2002). Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Medical and Pediatric Oncology, 39, 163-167.
47. Stover, L., Gorga, M., Neely, S., & Montoya, D. (1996). Toward optimizing the clinical utility of distortion product otoacoustic emission measurements. Journal of the Acoustical Society of America, 100, 956-967.
48. Takeno, S., Harrison, R., Ibrahim, D., Wake, M., & Mount, R. (1994). Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hearing Research, 75, 93-102.
49. Taudy, M., Syka, J., Popelar, J., & Ulehlova, L. (1992). Carboplatin and cisplatin Ototoxicity in guinea pigs. Audiology, 31, 293-299.
50. Wagner, W., & Plinkert, P. (1999). The relationship between auditory threshold and evoked otoacoustic emissions. European Archives of Otorhinolaryngology, 256, 177-188.
51. Wake, M., Takeno, S., Ibrahim, D., & Harrison, R. (1994). Selective inner hair cell ototoxicity induced by carboplatin. Laryngoscope, 104, 488-493.
52. Wang, J., Powers, N., Hofstetter, P., Trautwein, P., Ding, D., & Salvi, R. (1997). Effects of inner hair cell loss on auditory nerve fibre threshold, tuning and spontaneous and driven discharge rate. Hearing Research, 107, 67-82.
53. Watanabe, K., Jinnouchi, K, Hess, A., Michel, O., Baba, S., & Yagi, T. (2002). Carboplatin induces less apoptosis in the cochlea of guinea pigs than cisplatin. Chemotherapy, 48, 82-87.
54. Waters, G., Ahmad, M., Katsarkas, A., Stanmir, G., & McKay, J. (1991). Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: Influence of dosage and schedule of administration. Ear and Hearing, 12, 91-102.
55. Whitehead, M., Lonsbury-Martin, B., & Martin, G. (1993). The influence of noise on the measured amplitudes of distortion-product otoaeoustic emissions. Journal of Speech and Hearing Research, 36, 1097-1102.
56. Zorowka, P, Schmitt, H., & Gutjahr, P. (1993). Evoked otoaeoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy. International Journal of Pediatric Otorhinolaryngology, 25, 73-80.